Alternative medicine (1)
- Pet therapy: Man's best friend as healer
- Alzheimer's: Managing sleep problems
Coping and support (4)
- Caregiver stress: Tips for taking care of yourself
- Caregiving: Tips for long-distance caregivers
- Alzheimer's: Tips to make holidays more enjoyable
- see all in Coping and support
- Early-onset Alzheimer's: When symptoms begin before age 65
Lifestyle and home remedies (1)
- Mediterranean diet recipes
- Home safety tips: Preparing for Alzheimer's caregiving
- Alzheimer's stages: How the disease progresses
- Alzheimer's or depression: Could it be both?
- Memory loss: When to seek help
Tests and diagnosis (4)
- SPECT scan
- Diagnosing Alzheimer's: An interview with a Mayo Clinic specialist
- Sharing Alzheimer's diagnosis: Tips for caregivers
- see all in Tests and diagnosis
Treatments and drugs (3)
- Alzheimer's: 7 tips for medical visits
- Alzheimer's: Drugs help manage symptoms
- Alzheimer's treatments: What's on the horizon?
Alzheimer's: Drugs help manage symptoms
Memantine for later stages
Memantine (Namenda) is approved by the FDA for treatment of moderate to severe Alzheimer's disease. It works by regulating the activity of glutamate, a messenger chemical widely involved in brain functions — including learning and memory. It's taken as a pill or syrup. Common side effects include dizziness, headache, confusion and agitation.
Since memantine's original approval for moderate to severe Alzheimer's, researchers have conducted additional studies to determine whether memantine might also help in earlier stages. But none of this additional work shows that memantine has any benefit for mild Alzheimer's disease. Taking memantine also hasn't proven to help prevent progression of MCI to Alzheimer's disease.
When to discontinue Alzheimer's drugs
Because Alzheimer's is a progressive disease, your symptoms and care plan will change over time. If you're taking an Alzheimer's drug, ongoing review of your care plan will include working with your doctor to decide how long you should continue your medication. It may be difficult to tell if Alzheimer's drugs are helping, because their effect is usually modest. On the other hand, it's hard to know how severe your symptoms might be without your medication. If you stop taking an Alzheimer's drug and experience a sharp decline in your condition, contact your doctor. He or she may advise restarting the medication.Previous page
(2 of 2)
- Agency for Healthcare Research and Quality National Guideline Clearinghouse. Guideline synthesis: Management of Alzheimer's disease and related dementias. http://www.guidelines.gov/syntheses/synthesis.aspx?id=16414. Accessed May 31, 2011.
- Alzheimer's Association. New York Consortium for Alzheimer's Research and Education. News in AD treatment: Aricept generic and Aricept 23 mg. http://www.alznyc.org/nyc/newsletter/spring2011/21.asp. Accessed May 31, 2011.
- Food and Drug Administration Center for Drug Evaluation and Research. Summary review: Application number 022568 [for Aricept 23 mg]. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000SumR.pdf. Accessed May 31, 2011.
- Schneider LS, et al. Treatment with cholinesterase inhibitors and memantine in the Alzheimer's Disease Neuroimaging Initiative. Archives of Neurology. 2011;68:58.
- Schneider LS, et al. Lack of evidence for the efficacy of memantine in mild Alzheimer's disease. Archives of Neurology. In press. Accessed June 1, 2011.
- Salloway S. New lessons from the Alzheimer's Disease Neuroimaging Initiative. Archives of Neurology. 2011;68:19.
- Alzheimer's Association. Medications for memory loss. http://www.alz.org/alzheimers_disease_standard_prescriptions.asp. Accessed June 1, 2011.
- Loy C, et al. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews. 2009:CD001747.
- Press D, et al. Treatment of dementia. www.uptodate.com. Accessed June 2, 2011.
- Press D, et al. Cholinesterase inhibitors in the treatment of dementia. www.uptodate.com. Accessed June 2, 2011.
- Raschetti R, et al. Cholinesterase inhibitors in mild cognitive impairment: A systematic review of randomized trials. PLOS Medicine. 2007;4:e338. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2082649/pdf/pmed.0040338.pdf. Accessed June 3, 2011.